JP2013504523A - 抗癌薬としての置換(ヘテロアリールメチル)チオヒダントイン - Google Patents

抗癌薬としての置換(ヘテロアリールメチル)チオヒダントイン Download PDF

Info

Publication number
JP2013504523A
JP2013504523A JP2012528249A JP2012528249A JP2013504523A JP 2013504523 A JP2013504523 A JP 2013504523A JP 2012528249 A JP2012528249 A JP 2012528249A JP 2012528249 A JP2012528249 A JP 2012528249A JP 2013504523 A JP2013504523 A JP 2013504523A
Authority
JP
Japan
Prior art keywords
methyl
group
trifluoromethyl
oxo
dimethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2012528249A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013504523A5 (cg-RX-API-DMAC10.html
Inventor
ウルリッヒ・リュッキング
アルヴェート・クレーフェ
ベルナール・エンドレ
オルテンシア・ファウス・ヒメネス
ジルケ・ケーア
ホルスト・イルルバッハー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of JP2013504523A publication Critical patent/JP2013504523A/ja
Publication of JP2013504523A5 publication Critical patent/JP2013504523A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2012528249A 2009-09-11 2010-08-28 抗癌薬としての置換(ヘテロアリールメチル)チオヒダントイン Withdrawn JP2013504523A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP09075421.9 2009-09-11
EP09075421 2009-09-11
EP10075069.4 2010-02-17
EP10075069 2010-02-17
PCT/EP2010/005297 WO2011029537A1 (en) 2009-09-11 2010-08-28 Sustituted ( heteroarylmethyl ) thiohydantoins as anticancer drugs

Publications (2)

Publication Number Publication Date
JP2013504523A true JP2013504523A (ja) 2013-02-07
JP2013504523A5 JP2013504523A5 (cg-RX-API-DMAC10.html) 2013-10-17

Family

ID=42782041

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012528249A Withdrawn JP2013504523A (ja) 2009-09-11 2010-08-28 抗癌薬としての置換(ヘテロアリールメチル)チオヒダントイン

Country Status (28)

Country Link
US (1) US20120251551A1 (cg-RX-API-DMAC10.html)
EP (1) EP2475653A1 (cg-RX-API-DMAC10.html)
JP (1) JP2013504523A (cg-RX-API-DMAC10.html)
KR (1) KR20120065396A (cg-RX-API-DMAC10.html)
CN (1) CN102639523A (cg-RX-API-DMAC10.html)
AR (1) AR078166A1 (cg-RX-API-DMAC10.html)
AU (1) AU2010294588A1 (cg-RX-API-DMAC10.html)
BR (1) BR112012005526A2 (cg-RX-API-DMAC10.html)
CA (1) CA2773591A1 (cg-RX-API-DMAC10.html)
CL (1) CL2012000623A1 (cg-RX-API-DMAC10.html)
CO (1) CO6511228A2 (cg-RX-API-DMAC10.html)
CR (1) CR20120113A (cg-RX-API-DMAC10.html)
CU (1) CU20120042A7 (cg-RX-API-DMAC10.html)
DO (1) DOP2012000063A (cg-RX-API-DMAC10.html)
EA (1) EA201200473A1 (cg-RX-API-DMAC10.html)
EC (1) ECSP12011716A (cg-RX-API-DMAC10.html)
IL (1) IL218390A0 (cg-RX-API-DMAC10.html)
IN (1) IN2012DN02081A (cg-RX-API-DMAC10.html)
MA (1) MA33566B1 (cg-RX-API-DMAC10.html)
MX (1) MX2012002977A (cg-RX-API-DMAC10.html)
NZ (1) NZ598643A (cg-RX-API-DMAC10.html)
PE (1) PE20121180A1 (cg-RX-API-DMAC10.html)
PH (1) PH12012500497A1 (cg-RX-API-DMAC10.html)
SG (1) SG178919A1 (cg-RX-API-DMAC10.html)
TN (1) TN2012000108A1 (cg-RX-API-DMAC10.html)
TW (1) TW201111378A (cg-RX-API-DMAC10.html)
UY (1) UY32882A (cg-RX-API-DMAC10.html)
WO (1) WO2011029537A1 (cg-RX-API-DMAC10.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016540819A (ja) * 2013-12-19 2016-12-28 アンドルシェルシュ・インコーポレイテッド ピリジル部分を有する非ステロイド性抗アンドロゲン及び選択的アンドロゲン受容体モジュレーター

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3533797B1 (en) 2010-02-17 2023-12-20 Takeda Pharmaceutical Company Limited Heterocyclic compound
AU2011261164A1 (en) * 2010-06-01 2012-12-13 The University Of Queensland Haematopoietic-prostaglandin D2 synthase inhibitors
KR102072041B1 (ko) 2011-12-22 2020-01-31 앨리오스 바이오파마 인크. 치환된 뉴클레오사이드, 뉴클레오타이드 및 그의 유사체
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
PT2861611T (pt) 2012-05-25 2016-10-11 Janssen Sciences Ireland Uc Nucleósidos de espirooxetano de uracilo
TW201418243A (zh) 2012-11-15 2014-05-16 Bayer Pharma AG 含有磺醯亞胺基團之n-(吡啶-2-基)嘧啶-4-胺衍生物
US9243022B2 (en) 2012-12-21 2016-01-26 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
WO2014153280A1 (en) * 2013-03-22 2014-09-25 Merck Sharp & Dohme Corp. 2-pyridyl carboxamide-containing spleen tyrosine kinase (syk) inhibitors
CN104341351B (zh) * 2013-07-30 2018-02-06 北京海美源医药科技有限公司 一种二芳基硫代乙内酰脲衍生物及其应用
CA3161836A1 (en) * 2013-12-11 2015-06-18 Celgene Quanticel Research, Inc. Inhibitors of lysine specific demethylase-1
CN105829296A (zh) 2013-12-18 2016-08-03 巴斯夫欧洲公司 带有亚胺衍生的取代基的唑类化合物
CN103896847B (zh) * 2014-04-09 2016-01-20 沈江 一种非甾体类抗雄激素化合物及其制备方法和应用
JP6479854B2 (ja) 2014-05-07 2019-03-06 エヴォテック・インターナショナル・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングEvotec International GmbH 医薬組成物のためのスルホキシイミン置換キナゾリン
TWI656121B (zh) 2014-08-04 2019-04-11 德商拜耳製藥公司 2-(嗎啉-4-基)-1,7-萘啶
CN106187905B (zh) * 2015-05-05 2020-02-21 北京海步医药科技股份有限公司 丁鲁他胺的结晶形式及其制备方法
ES2819869T3 (es) 2015-10-08 2021-04-19 Bayer Pharma AG Nuevos compuestos macrocíclicos modificados
WO2017060322A2 (en) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Ptefb-inhibitor-adc
TWI726969B (zh) 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
EP3601253B1 (en) 2017-03-28 2021-09-15 Bayer Aktiengesellschaft Novel ptefb inhibiting macrocyclic compounds
CA3057891A1 (en) 2017-03-28 2018-10-04 Bayer Aktiengesellschaft Novel ptefb inhibiting macrocyclic compounds
EP3625215B1 (en) 2017-05-18 2023-09-13 PI Industries Ltd Formimidamidine compounds useful against phytopathogenic microorganisms
US11701347B2 (en) 2018-02-13 2023-07-18 Bayer Aktiengesellschaft Use of 5-fluoro-4-(4-fluoro-2-methoxyphenyl)-N-{4-[(S-methylsulfonimidoyl)methyl]pyridin-2-yl}pyridin-2-amine for treating diffuse large B-cell lymphoma
EP3953342B1 (en) 2019-04-11 2025-09-24 University of Miami Improved inhibitors of the notch transcriptional activation complex and methods for use of the same
US20230135524A1 (en) * 2020-01-21 2023-05-04 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Aryl hydantoin heterocycles and methods of use
WO2022206742A1 (zh) * 2021-03-30 2022-10-06 苏州开拓药业股份有限公司 一种一步法合成乙内酰硫脲衍生物的方法
CN122249431A (zh) * 2023-11-17 2026-06-19 中国药科大学 作为雄激素受体(ar)拮抗剂的化合物及其应用
CN120309588B (zh) * 2025-06-10 2025-08-12 上海健康医学院 一种具有雄激素受体和组蛋白去乙酰化酶6双重抑制作用的乙内酰硫脲类化合物及其用途

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2693461B1 (fr) * 1992-07-08 1994-09-02 Roussel Uclaf Nouvelles phénylimidazolidines substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
FR2671348B1 (fr) 1991-01-09 1993-03-26 Roussel Uclaf Nouvelles phenylimidazolidines, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant.
US5411981A (en) 1991-01-09 1995-05-02 Roussel Uclaf Phenylimidazolidines having antiandrogenic activity
USRE35956E (en) 1991-01-09 1998-11-10 Roussel Uclaf Phenylimidazolidines having antiandrogenic activity
FR2694290B1 (fr) 1992-07-08 1994-09-02 Roussel Uclaf Nouvelles phénylimidazolidines éventuellement substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
TW521073B (en) 1994-01-05 2003-02-21 Hoechst Marion Roussel Inc New optionally substituted phenylimidazolidines, their preparation process, their use as anti-androgenic agent and the pharmaceutical compositions containing them
FR2716110B1 (fr) 1994-02-16 1996-04-05 Roussel Uclaf Compositions cosmétiques ou pharmaceutiques comprenant des liposomes.
US5656651A (en) 1995-06-16 1997-08-12 Biophysica Inc. Androgenic directed compositions
WO2000017163A1 (en) 1998-09-22 2000-03-30 Yamanouchi Pharmaceutical Co., Ltd. Cyanophenyl derivatives
US6472415B1 (en) 1998-12-18 2002-10-29 Biophysica, Inc. Androgen receptor suppressors in the therapy and diagnosis of prostate cancer, alopecia and other hyper-androgenic syndromes
US6861432B2 (en) 2001-11-23 2005-03-01 Schering Aktiengesellschaft Piperazine derivatives that destabilize androgen receptors
JP2005532291A (ja) 2002-04-12 2005-10-27 ファイザー株式会社 抗炎症薬および鎮痛薬としてのピラゾール化合物
CA2529292A1 (en) 2003-07-02 2005-01-20 Merck & Co., Inc. Oxazolidinone antibiotics and derivatives thereof
AR045955A1 (es) 2003-09-30 2005-11-16 Janssen Pharmaceutica Nv Compuestos benzoimidazolicos
EP2228369A1 (en) 2003-12-23 2010-09-15 Astex Therapeutics Ltd. Pyrazole derivatives as protein kinase modulators
WO2006013887A1 (ja) 2004-08-03 2006-02-09 Chugai Seiyaku Kabushiki Kaisha 新規イミダゾリジン誘導体
KR20070106969A (ko) * 2004-09-09 2007-11-06 추가이 세이야쿠 가부시키가이샤 신규 이미다졸리딘 유도체 및 그 용도
MX2007006387A (es) 2004-12-03 2007-06-20 Hoffmann La Roche Derivados de piridina 3-substituidos como antagonistas h3.
NZ564223A (en) 2005-05-13 2011-03-31 Univ California Diarylhydantoin compounds for treating hormone refractory prostate cancer
US7709516B2 (en) 2005-06-17 2010-05-04 Endorecherche, Inc. Helix 12 directed non-steroidal antiandrogens
NZ596260A (en) 2006-03-29 2013-05-31 Univ California Diarylthiohydantoin compounds
TWI469971B (zh) 2007-10-26 2015-01-21 Univ California 二芳基乙內醯脲類化合物
WO2009097995A1 (de) * 2008-02-07 2009-08-13 Sanofi-Aventis Neue phenyl-substituierte imidazolidine, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016540819A (ja) * 2013-12-19 2016-12-28 アンドルシェルシュ・インコーポレイテッド ピリジル部分を有する非ステロイド性抗アンドロゲン及び選択的アンドロゲン受容体モジュレーター
JP2019055976A (ja) * 2013-12-19 2019-04-11 アンドルシェルシュ・インコーポレイテッド ピリジル部分を有する非ステロイド性抗アンドロゲン及び選択的アンドロゲン受容体モジュレーター

Also Published As

Publication number Publication date
CN102639523A (zh) 2012-08-15
UY32882A (es) 2011-04-29
AU2010294588A1 (en) 2012-04-05
CA2773591A1 (en) 2011-03-17
CL2012000623A1 (es) 2012-09-14
NZ598643A (en) 2013-10-25
IN2012DN02081A (cg-RX-API-DMAC10.html) 2015-08-21
MX2012002977A (es) 2012-04-30
TW201111378A (en) 2011-04-01
SG178919A1 (en) 2012-04-27
DOP2012000063A (es) 2012-05-15
IL218390A0 (en) 2012-04-30
KR20120065396A (ko) 2012-06-20
WO2011029537A1 (en) 2011-03-17
ECSP12011716A (es) 2012-04-30
US20120251551A1 (en) 2012-10-04
AR078166A1 (es) 2011-10-19
TN2012000108A1 (en) 2013-09-19
CO6511228A2 (es) 2012-08-31
PH12012500497A1 (en) 2012-10-22
MA33566B1 (fr) 2012-09-01
CR20120113A (es) 2012-05-02
EP2475653A1 (en) 2012-07-18
CU20120042A7 (es) 2012-06-21
BR112012005526A2 (pt) 2016-04-26
PE20121180A1 (es) 2012-08-24
EA201200473A1 (ru) 2012-10-30

Similar Documents

Publication Publication Date Title
KR20120065396A (ko) 항암 약물로서의 치환된 (헤테로아릴메틸)티오히단토인
JP5728683B2 (ja) チロシンスレオニンキナーゼ阻害剤としての置換アミノキノキサリン
JP6181664B2 (ja) 置換トリアゾロピリジン類およびttk阻害剤としてのその使用
JP5805654B2 (ja) トリアゾロピリジン誘導体
US9555022B2 (en) Substituted triazolopyridines
JP5727002B2 (ja) 置換ヘテロサイクリルベンジルピラゾール類およびその使用
JP6001049B2 (ja) Mps−1キナーゼ阻害剤としての置換ベンズイミダゾール類
KR20110082570A (ko) Hif 억제제로서 사용하기 위한 헤테로방향족 화합물
CA2832310A1 (en) Substituted imidazopyridines and intermediates thereof
TW200911792A (en) Benzimidazole derivatives
AU2011252222A1 (en) Hydroxyalkyl benzyl pyrazoles, and use thereof for the treatment of hyperproliferative and angiogenic diseases
WO2012160029A1 (en) Substituted triazolopyridines
HK1170732A (en) Sustituted ( heteroarylmethyl ) thiohydantoins as anticancer drugs
DE102008057364A1 (de) Substituierte Aryl-Verbindungen und ihre Verwendung
HK1164851A (en) Heteroaromatic compounds for use as hif inhibitors
HK1177462B (en) Triazolopyridine derivatives

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20130321

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130827

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130827

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20131224